To explore whether vigorous endurance exercise (i.e., running a marathon) alters the magnitude of cardiac damage following myocardial ischemia-reperfusion injury in amateur athletes through using an ex vivo rat heart model of myocardial infarction…
ID
Source
Brief title
Condition
- Cardiac disorders, signs and symptoms NEC
- Vascular injuries
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary outcome parameter focuses on infarct size (= degree of cell death)
introduced by global IR in our ex vivo model of myocardial infarction which is
presened as a percentage of infarcted tissue relative to the total ventricular
tissue.
Secondary outcome
Isolated rat Heart
- The release of the damage marker Lactate Dehydrogenase (LDH) into the cardiac
effluent during reperfusion due to cardiac damage.
- The restoration of mechanical function of the heart. Before starting the
experimental protocol, a balloon will be introduced into the left ventricle to
measure left ventricular pressure. This allows changes in developed pressure
before and after the introduction of ischemia to be examined.
- Protein changes that can provide information about intracellular mechanism
will be investigated by Western blot analysis. Alterations in adverse and
cardioprotective signalling pathways will be considered.
Participant blood samples
- Participants are assessed on concentrations of markers of injury or stress in
plasma (cardiac Troponin T/I, LDH and Creatine Kinase). Plasma samples are
collected before, after, and 4 hours after completion of the marathon. Residual
plasma is stored at -80 * for a maximum of 15 years for subsequent analysis.
Background summary
The cardiovascular health benefits of exercise are substantial, leading to
significant reductions in both all-cause and cardiovascular mortality.
Nonetheless, evidence is arising that vigorous endurance exercise might also
establish acute injury as established by the release of cardiac troponin, a
validated marker of cardiac injury. Besides the release of troponin, acute
bouts of vigorous exercise also promotes cardiovascular dysfunction and
transiently increase the risk for sudden cardiac death.
Prolonged exercise-induced cardiac strain potentially impacts the heart
negatively through transient ischemia, biochemical changes from increased
metabolism, and mechanical stress from overstretching. These factors,
individually or combined, may heighten the heart's vulnerability to the
magnitude of cardiac damage, such as exaggerated injury following myocardial
ischemia and reperfusion (IR). However, relatively little is known whether
strenuous exercise alters the magnitude of cardiac damage to IR injury.
Study objective
To explore whether vigorous endurance exercise (i.e., running a marathon)
alters the magnitude of cardiac damage following myocardial
ischemia-reperfusion injury in amateur athletes through using an ex vivo rat
heart model of myocardial infarction.
Study design
Exploratory and observational research
Study burden and risks
The experimental procedures are observational and only minimally invasive,
during blood sampling. Blood sampling, a commonly performed medical procedure,
poses no risks, particularly because it is carried out by individuals with
extensive experience. The only potential adverse effect is the formation of a
small hematoma. However, the incidence of this is low (5%), it is completely
reversible, and it does not interfere with daily life. The volunteers will not
benefit from participating in this study.
Reinier Postlaan 4
Nijmegen 6525GC
NL
Reinier Postlaan 4
Nijmegen 6525GC
NL
Listed location countries
Age
Inclusion criteria
- Healthy male volunteers, adults >18 years, <65 years.
- BMI < 30kg/m2
- Recreational athlete (i.e. minimal 1h/week exercise, maximal 5 days/week of
exercise)
- Free of cardiovascular disease
- Participants must be enrolled in the respective marathon event.
- No use of medication that alters the effect of cardioprotective signalling:
o β-blockers
o Calcium Channel blockers
o Nitrates
o Opioids
o Anti-platelet agents (e.g. paracetamol, ibuprofen)
o Statins and anti-hyperlipidaemic drugs
o Anti-diabetic treatment
Exclusion criteria
A potential subject who meets any of the following criteria will be excluded
from participation in this study:
- Presence of an absolute contra-indication for the performance of exercise.
- Mental impairment leading to inability to cooperate
- Participants are instructed to limit the amount of moderate to vigorous
exercises 48 hours before the start of the marathon. This is to prevent a
potential cardioprotective phenotype before the start of the study.
Participants that have not adhered to the restrictions will be excluded from
the study.
- Participants will be excluded in case they do not complete the marathon.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL88985.091.25 |